Change in management at GILUPI GmbH
Alexander Herrmann starts as new managing director at the medical device company
Having a master degree in Business Administration, Alexander Herrmann (43) counts many years of experience in leadership at biotechnology companies. He is supposed to speed-up the GILUPI CellCollector® marketing as well as the necessary restructuring of the company.
Mr. Herrmann commented: “The GILUPI CellCollector® is a unique and innovative product. Our target for the coming months is to enhance the GILUPI CellCollector® application by adding further molecular analytical tools, thus making the application even more valuable for our customers. Moreover, we will upscale our production capacity in Greifswald and complement our team by additional experts.
GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.
Individual oncological targeted therapies will become more and more important in tomorrow's personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly "fishing" them in the patient's bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.
For further information visit www.gilupi.com
Press releases you might also be interested in
Weitere Informationen zum Thema "Medizintechnik":
Künstliche Intelligenz in der Cybersecurity
Der derzeit heiß diskutierte Einsatz künstlicher Intelligenz in der Cybersecurity weckt Begehrlichkeiten: Allzugern würden manche Anwender den Großteil der teuren und zermürbenden Arbeit im SOC komplett den KI-Systemen überlassen. Wirklich schlagkräftig und hinreichend nebenwirkungsfrei arbeitet KI aber nur im Team mit menschlicher Intelligenz.Weiterlesen